The health and welfare of animals is at the heart of a thriving and sustainable food chain. We are investing in new animal healthcare technologies to solve major production challenges in aquaculture and agriculture.
We have recently invested £16 million expanding and upgrading our UK vaccine manufacturing facility. The new 2,500-square-meter facility enables a seamless transition from R&D through to production.
Building our technology platform
Our product development team works alongside commercial experts to identify the challenges facing our partners and clients. Our in-house trial units and manufacturing facilities allow us to overcome bottlenecks in development and efficiently progress products through to market.
We have recently expanded capacity at our UK vaccine manufacturing facility. The new £16 million 2,500-square-meter facility enables a seamless transition from R&D to production and improved efficiency and flexibility combining both conventional and recombinant vaccines, including Virus Like Particles (VLP).
"Our focus is on exploring and utilising the most powerful and effective vaccine science and technology in order to efficiently manufacture innovative products"Bob Long, Managing Director
Benchmark Vaccines LTD